The efficacy and safety of preemptive therapy using ganciclovir (GCV) 5 mg/kg once daily for CMV infection after unrelated cord blood transplantation (CBT) were studied. The initial preemptive therapy with GCV 5 mg/kg once daily led to resolution of CMV antigenemia in 25 of 34 patients (74%). In the remaining 9 patients (26%), antigenemia resolved after dose-escalation of GCV or change to foscarnet therapy. Recurrence of antigenemia was seen in 18 patients (53%). A total of 12 patients received the second preemptive therapy with GCV 5 mg/ kg once daily, which led to resolution of antigenemia in 11 of 12 patients (92%). The remaining 1 patient (8%) required change to foscarnet therapy. None of 34 patients developed CMV disease. Neutropenia with an absolute neutrophil number of less than 1 and 0.5 Â 10 9 per liter after GCV therapy occurred in 12 (35%) and 1 (3%) patients, respectively, after the initial therapy, and in 2 (17%) and 0 (0%) patients, respectively, after the second therapy. No patients developed neutropenic fever or secondary graft failure after GCV therapy. There were no deaths directly attributable to GCV therapy. The present study suggests that antigenemia-based preemptive strategy using GCV 5 mg/kg once daily is feasible and effective for CBT recipients.
Introduction
CMV disease is one of the major infectious complications after allogeneic hematopoietic SCT. 1, 2 By applying various surveillance methods such as antigenemia and PCR assays, preemptive strategies with ganciclovir (GCV) have been widely used for preventing early CMV disease after SCT. In most preemptive strategies, GCV is administered intravenously at a dose of 5 mg/kg twice daily as an initial induction phase for 1-2 weeks, then followed by 6 mg/kg once daily as a maintenance phase. 3 One of the major adverse effects of GCV is neutropenia. 4 In an attempt to reduce the incidence of GCV-related neutropenia, preemptive therapy with GCV 5 mg/kg once daily has previously been used as initial induction therapy for BMT and peripheral blood SCT (PBSCT) recipients. [5] [6] [7] The favorable outcomes suggested that this strategy could reduce the incidence of GCV-related neutropenia but retained the efficacy for preventing CMV disease in BMT and PBSCT recipients.
Umbilical cord blood transplantation (CBT) from an unrelated donor has recently been utilized as an alternative therapy for patients who do not have suitable donors for BMT or PBSCT. 8, 9 Previous studies have shown that CMV infection occurs frequently in adult patients after CBT. 10, 11 In addition, patients with CMV infection after CBT have a higher probability of secondary graft failure than those without CMV infection. 11 Toxicity of GCV may be associated with secondary graft failure in CBT recipients with CMV infection.
In our previous study, we reported the results of antigenemia-based preemptive GCV therapy for CMV infection in adult patients after unrelated CBT. 12 The preemptive therapy consisted of GCV 5 mg/kg twice daily as an initial induction phase for 2 weeks and 5 mg/kg once daily as a maintenance phase for 1 week or more. Because of recent favorable outcomes in BMT and PBSCT recipients, we examined the efficacy and toxicity of preemptive therapy using GCV 5 mg/kg once daily for CMV infection after unrelated CBT in the present study.
Patients and methods

Patients
Between May 2002 and April 2006, 60 patients underwent CBT using a conditioning regimen containing 12 Gy total body irradiation. Among them, 34 patients who developed CMV antigenemia and initially received preemptive therapy with GCV 5 mg/kg once daily were analyzed in the present study. Patient characteristics are listed in Table 1 . The remaining 26 patients were excluded from the analysis for the following reasons. Four patients did not achieve cord blood-derived myeloid engraftment. A total of 16 patients including 8 CMV-seronegative patients did not develop antigenemia during the first 90 days after CBT. The remaining 6 patients received GCV therapy, but the initial dose was not 5 mg/kg once daily. Two patients with a creatinine clearance rate (CCR) of less than 30 ml/min initially received GCV 2 or 3 mg/kg once daily. Two patients with pulmonary symptoms and signs initially received GCV 5 mg/kg twice daily. In both patients, organizing pneumonia but not CMV pneumonia was diagnosed with transbronchial lung biopsy specimens. 13 The remaining two patients who did not have pulmonary symptoms or renal dysfunction received GCV 5 mg/kg twice daily, but there were no specific reasons for choosing the conventional-dose GCV therapy. Therefore, preemptive therapy with GCV 5 mg/kg once daily was applied to patients who did not have pulmonary symptoms possibly due to CMV pneumonia or renal dysfunction with a CCR of less than 30 ml/min at the initiation of GCV therapy.
Transplantation procedures and supportive care
Transplantation procedures and supportive care were described previously. 14 The preparative regimen and GVHD prophylaxis are described in Table 1 . All patients received 1000 mg per day acyclovir orally from day À3 to day þ 35 to prevent herpes simplex virus infection. To facilitate neutrophil engraftment, recombinant human G-CSF was administered intravenously at a dose of 5 mg/ kg per day from day þ 1 after CBT. G-CSF administration was discontinued when an ANC increased to more than 3 Â 10 9 per liter irrespective of whether patients were during GCV therapy or not.
Preemptive GCV therapy CMV infection was monitored using an antigenemia assay twice a week after engraftment. The antigenemia assay consisted of direct immunostaining of polymorphonuclear leukocytes with monoclonal antibodies C10/C11 (Clonab CMV; Biotest, Dreieich, Germany). The results are expressed as the number of antigen-positive cells per 3 Â 10 5 cells on two slides. Preemptive GCV therapy was initiated when one or more positive cells were detected on two slides. GCV was administered intravenously at a dose of 5 mg/kg once daily. GCV therapy was discontinued when neutropenia with an ANC of less than 1 Â 10 9 per liter developed, or when negative results on two or more consecutive tests were obtained. When antigenemia test results worsened after GCV therapy, the dose of GCV was increased to 5 mg/kg twice daily or GCV was changed to foscarnet.
Statistical methods
The frequencies of categorical variables were compared using the Fisher's exact test. The values of antigenemia test results between two groups were compared using the Mann-Whitney U-test.
Results
Initial preemptive therapy with GCV 5 mg/kg once daily Preemptive therapy with GCV 5 mg/kg once daily was initiated at a median of 35 days (range 21-71) after CBT. The median value of the antigenemia test result was two cells (range 1-29) at the initiation of GCV therapy. In 23 of 
LD-GCV indicates low-dose (5 mg/kg once daily) ganciclovir therapy. a Low-risk diseases were defined as acute leukemia and lymphoma in the first or second complete remission, myelodysplastic syndrome in early phases and chronic myelogenous leukemia in the first chronic phase. Highrisk diseases were defined as those other than the above. b The matching of HLA-A and -B was confirmed by low-resolution typing methods, and the matching of HLA-DRB1 was confirmed by highresolution typing methods.
34 (68%) patients, GCV therapy was completed after consecutive negative results on the antigenemia test (Table 2 ). In other two (6%) patients, GCV therapy was discontinued because of the development of neutropenia with an ANC of less than 1 Â 10 9 per liter. However, the two patients achieved consecutive negative results on the antigenemia test after the discontinuation of GCV therapy. For these 25 (74%) patients, preemptive therapy with GCV 5 mg/kg once daily led to the resolution of antigenemia. The resolution of antigenemia was first achieved within 6 and 13 days after the initiation of GCV therapy in 10 (29%) and 18 (53%) patients, respectively. The median duration of GCV therapy in these 25 patients was 16 days (range 8-45). In contrast, therapy with GCV 5 mg/kg once daily was discontinued in the remaining nine (26%) patients because of increasing antigenemia values; the GCV dose was increased to 5 mg/kg twice daily in eight patients a median of 11 days (range 5-13) after the initiation of preemptive GCV therapy, and GCV was changed to foscarnet in one patient of 13 days after the initiation of GCV therapy. The reason for choosing foscarnet in this patient was that the ANC decreased to 1.35 Â 10 9 per liter after 11 days of preemptive GCV therapy. After dose-escalation of GCV or changing to foscarnet therapy, consecutive negative results on the antigenemia test were obtained in all nine patients. In eight patients who required dose-escalation of GCV, the total duration of GCV therapy was 24 days (range 21-29).
Recurrence of antigenemia and second GCV therapy Of the 34 patients who received initial preemptive therapy with GCV, 5 mg/kg once daily, 18 (53%) patients developed antigenemia again after completion of the therapy ( Table 2 ). The median onset was 74 days (range 42-116) after CBT. Among them, four patients who developed antigenemia with a value of only one cell did not receive further antiviral therapy, because antigenemia resolved spontaneously. The second course of preemptive therapy for the remaining 14 (41%) patients was initiated a median of 72 days (range 43-106) after CBT. The median value of the antigenemia test result was three cells (range 1-11) on initiation of the second course of therapy. The antiviral agent was GCV in 12 patients and foscarnet in 2. The GCV dose was 5 mg/kg once daily in all 12 patients. In one patient who received the second course of GCV therapy, GCV was changed to foscarnet 13 days after the initiation of GCV therapy because of an increasing antigenemia value. Positive antigenemia test results in the patient resolved 8 days after the initiation of foscarnet therapy. In the remaining 11 patients, preemptive therapy with 5 mg/kg once daily was completed after consecutive negative results on the antigenemia test. The median duration of GCV therapy in the 11 patients was 15 days (range 11-22). In two patients who received the second course of preemptive therapy with foscarnet, antiviral therapies for 12 and 17 days were completed after consecutive negative results on the antigenemia test. However, 4 of 14 patients received one or two further courses of antiviral therapy for the recurrence of antigenemia.
CMV disease CMV disease did not occur in the 34 patients who initially received preemptive therapy with GCV 5 mg/kg once daily. However, CMV disease occurred in one patient who was excluded from the analysis. The patient had renal dysfunction with a CCR of 25 ml/min and received preemptive therapy with GCV 3 mg/kg once daily for antigenemia from day þ 22. Because of an increasing antigenemia value, the antiviral agent was changed to foscarnet on day þ 33 after CBT. Foscarnet therapy was continued after the resolution of antigenemia. CMV meningitis occurred on day þ 111, which did not respond to GCV therapy and directly caused her death.
Neutropenia after GCV therapy
The incidence of neutropenia after the initial GCV therapy was examined. The median ANC at the initiation of GCV therapy was 1.9 Â 10 9 per liter (range 0.35-6.4 Â 10 9 per liter). In 17 of 34 (50%) patients, no obvious decrease in the ANC was observed after GCV therapy (Table 3 ). In the per liter. Among them, four of eight (50%) patients who had required dose-escalation of GCV after increasing antigenemia values were included. The median duration of neutropenia was 5 days (range 1-30). A total of 2 mg/kg G-CSF administration was initiated in four patients with ANCs of 0.44, 0.62, 0.7 and 0.92 Â 10 9 per liter. In these patients, the ANC increased to more than 1 Â 10 9 per liter within 2 days after the initiation of G-CSF administration. Neutropenia with an ANC of less than 0.5 Â 10 9 per liter occurred in only one (3%) patient.
Next, the incidence of neutropenia after the second course of GCV therapy was examined. The median ANC at the initiation of GCV therapy was 2.9 Â 10 9 per liter (range 1.23-5.23 Â 10 9 per liter). In 7 of 12 (58%) patients, no obvious decrease in the ANC was observed after GCV therapy. In the remaining five patients, the minimum ANC was a median of 1.27 Â 10 9 per liter (range 0.67-3.07 Â 10 9 per liter) which occurred a median of 14 days (range 13-30) after the initiation of GCV therapy. Two (17%) patients developed neutropenia with an ANC of less than 1 Â 10 9 per liter (0.67 and 0.69 Â 10 9 per liter). The durations of neutropenia were 5 and 9 days, respectively.
The association between G-CSF administration at the initiation of GCV therapy and the incidence of neutropenia after GCV therapy was examined. A total of 11 patients still received G-CSF at the initial course of GCV therapy, but none at the second course of therapy. After the initial GCV therapy, neutropenia less than 1 Â 10 9 per liter occurred in 3 of 11 (27%) patients with G-CSF administration, and 9 of 24 (37%) patients without G-CSF administration (P ¼ 0.42).
No patients developed neutropenic fever or infection after the initial and second courses of GCV therapy. Secondary graft failure did not occur. There were no deaths directly attributable to GCV therapy.
Thrombocytopenia after GCV therapy
At the initiation of GCV therapy, 24 of 34 (71%) patients had a platelet count of less than 20 Â 10 9 per liter and still required platelet transfusions. In the remaining 10 (29%) patients, a platelet count was between 20 and 50 Â 10 9 per liter in two patients, between 50 and 100 Â 10 9 per liter in six patients, and more than 100 Â 10 9 per liter in two patients. No patients showed obvious decrease in a platelet count during and after GCV therapy. In 19 of 24 (79%) patients who required platelet transfusions, a platelet count increased more than 20 Â 10 9 per liter without transfusions within 21 days after the initiation of GCV therapy. In all 10 patients who did not require platelet transfusions, the platelet count increased to more than 100 Â 10 9 per liter within 21 days.
During and after the second course of GCV therapy, no patients showed obvious decrease in a platelet count, either. Although only one (8%) patient still required platelet transfusions, his platelet count increased to more than 50 Â 10 9 per liter within 21 days after the initiation of GCV therapy. In four of six (67%) patients with a platelet count between 20 and 50 Â 10 9 per liter, a platelet count increased to more than 50 Â 10 9 per liter within 21 days. A platelet count between 50 and 100 Â 10 9 per liter in four patients and more than 100 Â 10 9 per liter in the remaining one patient increased to more than 100 and 200 Â 10 9 per liter, respectively. These results showed that the impact of preemptive therapy with GCV 5 mg/kg once daily on platelet recovery was relatively mild in patients after CBT.
Factors affecting the response of GCV therapy
The impacts of the severity of antigenemia, acute GVHD and steroid therapy were examined. Between 9 patients who had the increasing antigenemia test results during GCV therapy and 25 patients who did not, the values of an antigenemia test at the initiation of GCV therapy did not differ significantly (median, three cells (range 1-29) and median, two cells (range 1-18), respectively, P ¼ 0.41). Between 18 patients who had recurrence of antigenemia after the completion of the initial GCV therapy and 16 patients who did not, the values of an antigenemia test also did not differ (median, three cells (range 1-29) and median, two cells (range 1-7), respectively, P ¼ 0.82). Between 18 patients with grade II-IV acute GVHD and 16 patients without it, the probabilities of the increasing antigenemia test results did not differ significantly (28 and 25%, respectively, P ¼ 0.58). The probabilities of the recurrence of antigenemia also did not differ (56 and 50%, respectively, P ¼ 0.51). Between six patients who received steroid therapy with 0.5 mg/kg prednisolone or more and 28 patients who did not, the probabilities of the increasing antigenemia test results did not differ (50 and 21%, respectively, P ¼ 0.17). The probability of the recurrence of antigenemia in patients with steroid therapy was 83%, which also did not differ significantly from that in patients without steroid therapy (46%, P ¼ 0.11). However, the reason for the failure to detect significant differences between patients with and without steroid therapy was probably due to the small patient number in this study.
Discussion
In the present study, we examined the efficacy and toxicity of preemptive therapy using GCV 5 mg/kg once daily for CMV infection after unrelated CBT. In the entire cohort of 60 patients, CMV disease occurred in one patient who had severe renal dysfunction and was excluded from this preemptive strategy. However, CMV disease did not occur in 34 patients who received preemptive therapy with GCV 5 mg/kg once daily as the initial induction therapy. Because study patients were selected based on those who did not have possible CMV pneumonia or severe renal dysfunction, preemptive therapy with GCV 5 mg/kg once daily was suggested to be effective for such selected CBT recipients.
The efficacy of preemptive therapy with GCV 5 mg/kg once daily was compared with that in our previous study using conventional preemptive GCV therapy for CBT recipients 12 (Table 4) . Within 21 days after the initiation of GCV therapy, antigenemia resolved in 13 of 16 (81%) patients in the previous study and 31 of 34 (91%) patients in the present study. The remaining patients required prolonged administration of GCV. In the present study, nine (26%) patients developed increasing antigenemia values within 14 days after the initiation of GCV therapy and required dose-escalation of GCV or a change to foscarnet therapy. However, all patients in both studies achieved consecutive negative results on the antigenemia test without the development of CMV disease. In the previous study, 8 of 16 (50%) patients developed recurrence of antigenemia and 6 (37%) patients required one or more further courses of GCV therapy. Similarly, in the present study, 18 of 34 (53%) patients developed recurrence of antigenemia and 14 (41%) patients required one or more further courses of GCV therapy. In the entire study cohorts, none of the 28 (0%) patients in the previous study and 1 of the 60 (2%) patients in the present study developed CMV disease after CBT. These results suggest that the efficacy of a preemptive strategy using GCV 5 mg/kg once daily as initial induction therapy is largely equivalent to the conventional preemptive strategy using GCV 5 mg/kg twice daily as an initial induction phase for patients after CBT. The incidence of neutropenia after preemptive therapy with 5 mg/kg once daily was compared with that after conventional preemptive GCV therapy for CBT patients in our previous study 15 ( Figure 1 ). Neutropenia with an ANC of less than 1 and 0.5 Â 10 9 per liter after initial GCV therapy occurred in 12 (35%) and 1 (3%) of 34 patients, respectively, in the present study, and 9 (53%) and 2 (12%) of 17 patients, respectively, in the previous study. Although the incidences of neutropenia tended to be lower in the present study, statistical analysis did not show significant differences (P ¼ 0.18 for ANCo1 Â 10 9 liter and 0.25 for ANCo0.5 Â 10 9 per liter). However, the proportion of patients who did not show an obvious decrease in the ANC after GCV therapy in the present study was significantly higher than in the previous study (50 vs 12%, Po0.01). In both previous and present studies, no patients developed neutropenic fever or secondary graft failure after GCV therapy. There were no GCV therapy-related deaths in either study. These results suggest that a preemptive strategy using GCV 5 mg/kg once daily is feasible for patients after CBT. Favorable outcomes of preemptive therapy with GCV 5 mg/kg once daily for BMT and PBSCT recipients were previously reported. [5] [6] [7] In previous studies, dose-escalation of GCV or a change to foscarnet therapy was required in 32-39% patients when the initial response was not sufficient. Recurrence of CMV infection after the completion of initial preemptive therapy was observed in 33-43% patients. However, the incidence of CMV disease was less than 10% in all studies. In addition, GCV-related neutropenia occurred in only 3-16% patients. These results suggest that preemptive therapy with GCV 5 mg/kg once daily can reduce the incidence of GCV-related neutropenia but retain the efficacy for preventing CMV disease in BMT and PBSCT recipients.
The reported incidence of CMV infection after CBT ranges from 41 to 58% in CMV-seropositive patients. 11, 16 Among 48 CMV-seropositive patients who achieved neutrophil engraftment after CBT, 40 patients (83%) showed positive test results in the present study. This incidence of CMV infection after CBT might be higher than in the previous studies. The remaining eight CMVseropositive patients including three patients aged more than 40 years, six patients with grade II-IV acute GVHD and two patients in high-risk disease status, did not show positive antigenemia test results within 90 days after CBT. The incidence of documented CMV infection can vary depending on the monitoring strategy. 6 By using sensitive PCR methods instead of antigenemia assays, more frequent CMV infections after CBT would be identified.
The present study suggests that an antigenemia-based preemptive strategy using GCV 5 mg/kg once daily as the Figure 1 Serial changes in ANCs after ganciclovir (GCV) therapy. ANCs at 0, 7, 14, 21 and 28 days after the initiation of GCV therapy did not differ significantly between low-dose GCV therapy in the present study and conventional GCV therapy in the previous study 12 (Mann-Whitney U-test, P ¼ 0.09, 0.09, 0.53, 0.97 and 0.17, respectively). The dots represent a median ANC, and the horizontal lines represent 25th and 75th percentile. initial induction therapy is feasible and effective for CBT recipients. However, the study cohort included only patients who did not have possible CMV pneumonia or severe renal dysfunction. For a patient with possible CMV pneumonia, the initiation of therapy with GCV 5 mg/kg twice daily would be prudent, because of a high mortality of established CMV pneumonia. 1 For a patient with severe renal dysfunction, the GCV dose should be adjusted for the CCR of the patient. 17 Cord blood lymphocytes are functionally and phenotypically immature as compared with adult blood lymphocytes. 18 Therefore, preemptive strategy distinct from that for BMT or PBSCT recipients may be appropriate for CBT recipients. Large-scale studies are needed to determine the efficacy and safety of the preemptive strategy for preventing CMV disease in adult patients after CBT.
